(poor ovarian response
Conditions
Interventions
Luteal estrogen group (group A):After ovulation, oral estradiol valerate tablets (Bujiale, 1mg / tablet, Bayer Pharmaceuticals) 4 capsules, Qd, to the menstrual cramps day.
Luteal phase estrogen and progesterone combination group (group B):Oral estradiol tablets/estradiol dydrogesterone tablets after ovulation (Fentongtong, white tablets are 1 mg of estradiol tablets, gr
OC program group (group C):On the third day of menstruation, oral drospirenone ethinyl estradiol tablets (Yi Siming, each containing drospirenone 3 mg and ethinyl estradiol 0.03 mg, Bayer Medicine), 1
Estrogen and progesterone sequential group (group D):On the third day of menstruation, oral estradiol tablets/estradiol dydrogesterone tablets (fentopine, white tablets are 1 mg of estradiol tablets,
Blank group (group E):No pretreatment is required before COS.
All groups:Each group of patients was treated with menstrual cramps on the next menstrual cycle, and the start of rFSH (recombinant follicle stimulating hormone) was determined according to the patien
Sponsors
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
21 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients who met the low prognostic criteria of POSEIDON were treated with IVF for pregnancy due to simple fallopian tube factors (except hydrosalpinx). The criteria are as follows: 1. Elderly ovarian reserve group: (1) aged >=35 years; (2) ovarian markers: AFC (antral follicle count, antral follicle count, sinus follicle count) >=5, AMH >=1.2 ng/ml; (3) number of eggs obtained after standard stimuli: Suboptimal responders: =35 years 2 ovarian markers: AFC < 5, AMH < 1.2 ng / ml.
Exclusion criteria
Exclusion criteria: 1. internal surgery or gynecological malignant disease; 2. endocrine or metabolic diseases; 3. repeated failure to implant patients (with quality embryos but not pregnant, >=3 times); 4. endometrial lesions or submucosal uterine fibroids; 5. III to IV stage endometriosis or adenomyosis; 6. genital malformations; 7. history of thrombosis or family history of thrombosis; 8. patients with recurrent spontaneous abortion (two or more spontaneous abortions with the same partner); 9. fallopian tube water.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of eggs obtained;Follicular output rate;Fertility rate;Cumulative pregnancy rate;Cumulative live birth rate;Abortion rate;Gn starts daily blood value (FSH, E2, P);HCG daily blood value (FSH, E2, P);Egg blood value (E2, P);Transplant daily blood value (E2, P); | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum basal endocrine (E2, P, LH, FSH, PRL, T);AMH;Whether ectopic pregnancy occurs;Whether pregnancy hypertension occurs;Average fetal birth weight;Whether the fetus has a congenital abnormality; | — |
Countries
China
Contacts
Public ContactNing Zhang
Shandong University of Traditional Chinese Medicine
Outcome results
None listed